FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol

View source ↗

Summary

FDA approves Lipfendra (enlicitide), the first oral PCSK9 inhibitor, to reduce LDL cholesterol in adults with hypercholesterolemia as an adjunct to diet and exe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerotic Cardiovascular Disease Risk Reduction
• Hypercholesterolemia

Drugs mentioned

• Lipfendra (enlicitide)

Snippet

The U.S. Food and Drug Administration approved Lipfendra (enlicitide), the first oral inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C), or “bad” cholesterol, in adults with hypercholesterolemi